Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors.

Adam M Fontebasso, Breelyn A Wilky, Rebecca A Gladdy, Jean-Yves Blay, Jeffrey D Rytlewski

Journal: Surgical oncology clinics of North America 2024;33(2):387-408

PMID: 38401916

Full Text on Elsevier Science View on PubMed

Abstract

Soft tissue sarcomas (STSs), including gastrointestinal stromal tumors (GISTs), are mesenchymal neoplasms with heterogeneous clinical behavior and represent broad categories comprising multiple distinct biologic entities. Multidisciplinary management of these rare tumors is critical. To date, multiple studies have outlined the importance of biological characterization of mesenchymal tumors and have identified key molecular alterations which drive tumor biology. GIST has represented a flagship for targeted therapy in solid tumors with the advent of imatinib which has revolutionized the way we treat this malignancy. Herein, the authors discuss the importance of biological and molecular diagnostics in managing STS and GIST patients.

Address: Division of Surgical Oncology, Department of Surgery, University of Toronto, 700 University Avenue, 7th Floor, Ontario Power Generation Building, Toronto, Ontario, Canada; Department of Surgery, Mount Sinai Hospital, Sinai Health Systems, 600 University Avenue Room 6-445.10 Surgery, Toronto, Ontario M5G 1X5, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; University of Colorado School of Medicine, 12801 East 17th Avenue, Mailstop 8117, Aurora, CO 80045, USA.; Centre Léon Bérard, 28, rue Laennec, 69373 cedex 08. Lyon, France.; University of Colorado School of Medicine, 12801 East 17th Avenue, Mailstop 8117, Aurora, CO 80045, USA. Electronic address: [email protected].

DOI: 10.1016/j.soc.2023.12.018

Link outs

Free resources

Medical:

https://medlineplus.gov/softtissuesarcoma.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Gastrointestinal Stromal Tumors, Precision Medicine, Sarcoma, Soft Tissue Neoplasms, Imatinib Mesylate, Sodium Tetradecyl Sulfate